EGFR and non-small cell lung carcinoma: The phase I/II dose-escalation AURA trial evaluated the safety, efficacy, and tolerability of osimertinib in patients with advanced EGFR-mutated, T790M-positive NSCLC who received prior EGFR TKI therapy.